DBV Technologies' Viaskin Peanut Patch reduces reaction severity in Phase 3 trial in children

DBVT•2026-11-12

DBV Technologies said its Viaskin Peanut Patch met the primary endpoint in a Phase 3 trial of children ages 4–7, reducing allergic reaction severity versus placebo over 12 months.

DBV Technologies' Viaskin Peanut Patch reduces reaction severity in Phase 3 trial in children

1. Phase 3 results

Related News

Hartford Funds announces closure and liquidation of two exchange-traded funds

Vishay unit enters binding term sheet for semiconductor JV in India with Kaynes Technology

Nasdaq trade halt: volatility trading pause at 10:05 a.m.

Occidental Petroleum publishes Q3 2026 earnings call transcript

Nasdaq trade halt: volatility trading pause at 9:58 a.m.